X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (18) 18
index medicus (15) 15
endocrinology & metabolism (11) 11
osteoporosis (11) 11
postmenopausal women (11) 11
bone-mineral density (10) 10
care and treatment (10) 10
stem-cell transplantation (9) 9
induction treatment prior (8) 8
medicine & public health (8) 8
orthopedics (8) 8
multiple myeloma (7) 7
aged (6) 6
bone density conservation agents - therapeutic use (6) 6
endocrinology (6) 6
female (6) 6
fractures (6) 6
research (6) 6
rheumatology (6) 6
aged, 80 and over (5) 5
analysis (5) 5
bone density (5) 5
bones (5) 5
density (5) 5
drug therapy (5) 5
health aspects (5) 5
middle aged (5) 5
risk factors (5) 5
teriparatide (5) 5
teriparatide - therapeutic use (5) 5
zoledronic acid (5) 5
alendronate (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
bone mineral density (4) 4
combination therapy (4) 4
dosage and administration (4) 4
male (4) 4
osteoporosis - drug therapy (4) 4
parathyroid-hormone 1-34 (4) 4
randomized controlled-trial (4) 4
risk (4) 4
bortezomib (3) 3
combined modality therapy (3) 3
complications and side effects (3) 3
diagnosis (3) 3
fracture risk reduction (3) 3
gynecology (3) 3
high-dose therapy (3) 3
international staging system (3) 3
lenalidomide plus dexamethasone (3) 3
long-term survival (3) 3
multiple myeloma - drug therapy (3) 3
multiple myeloma - therapy (3) 3
oncology (3) 3
osteoporosis - complications (3) 3
osteoporosis, postmenopausal - drug therapy (3) 3
pharmacology & pharmacy (3) 3
prior antiresorptive treatment (3) 3
prior fracture (3) 3
stem cells (3) 3
thalidomide plus dexamethasone (3) 3
adult (2) 2
anabolic (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
antiresorptive (2) 2
article (2) 2
biochemical markers (2) 2
biomarkers - blood (2) 2
bmd (2) 2
bone density - drug effects (2) 2
bone density - physiology (2) 2
bone-marrow-transplantation (2) 2
boronic acids - therapeutic use (2) 2
chemotherapy, combination (2) 2
clinical trials (2) 2
clinical trials as topic (2) 2
denosumab (2) 2
dexamethasone (2) 2
elderly untreated patients (2) 2
elderly-patients (2) 2
endocrinology, diabetes and metabolism (2) 2
epidemiology (2) 2
femur (2) 2
fracture risk (2) 2
fractures, bone - etiology (2) 2
fractures, bone - physiopathology (2) 2
hematology (2) 2
hip (2) 2
hip fracture (2) 2
hip fractures - etiology (2) 2
hormone replacement therapy (2) 2
igm monoclonal gammopathy (2) 2
metaanalysis (2) 2
newly-diagnosed myeloma (2) 2
no prior therapy (2) 2
osteoporosis - physiopathology (2) 2
osteoporosis, postmenopausal - complications (2) 2
osteoporotic fractures (2) 2
parathyroid hormone (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Expert Review of Anticancer Therapy, ISSN 1473-7140, 11/2007, Volume 7, Issue 11, pp. 1517 - 1527
Radiation therapy can be an effective means to treat bone metastases, which occur in more than 50% of cancer patients. 153 Samarium lexidronam ( 153 Sm-EDTMP;... 
bone pain | leukemia | samarium | scintigraphy | marrow radiation | skeletal metastases | metastatic cancer | bone scan | external beam radiotherapy | lesion irradiation | prostate cancer | myeloma | radiation | radiosensitization | bone cancer | Sm-EDTMP | breast cancer chemotherapy | osteoblastic osseous metastases | osteosarcoma | Marrow radiation | Leukemia | Metastatic cancer | Osteoblastic osseous metastases | Radiation | Breast cancer chemotherapy | Scintigraphy | Myeloma | Bone cancer | Radiosensitization | Osteosarcoma | Bone pain | Skeletal metastases | External beam radiotherapy | Samarium | Lesion irradiation | Prostate cancer | Bone scan | Sm-153-EDTMP | BREAST-CANCER | LOW TOXICITY | PROSTATE-CANCER | STEM-CELL TRANSPLANTATION | PHASE-I | MULTIPLE-MYELOMA | ACUTE MYELOGENOUS LEUKEMIA | mycloma | DIAMINE TETRAMETHYLENE PHOSPHONATE | ONCOLOGY | RADIONUCLIDE THERAPY | MARROW ABLATION PRIOR | Bone Neoplasms - radiotherapy | Animals | Humans | Organophosphorus Compounds - therapeutic use | Bone Neoplasms - secondary | Organometallic Compounds - therapeutic use | Radioisotopes | Osteosarcoma - radiotherapy | Analgesics, Non-Narcotic - therapeutic use | Bone Neoplasms - pathology | Osteosarcoma - pathology | Care and treatment | Dosage and administration | Diagnosis | Research | Radiotherapy | Health aspects
Journal Article
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 08/2011, Volume 8, Issue 8, pp. 479 - 491
Journal Article
Expert Opinion on Emerging Drugs, ISSN 1472-8214, 09/2012, Volume 17, Issue 3, pp. 407 - 438
Introduction: Survival in multiple myeloma (MM) has improved significantly in the past 10 years due to new treatments, such as thalidomide and lenalidomide... 
multiple myeloma | new drugs | therapy | New drugs | Therapy | Multiple myeloma | INDUCTION TREATMENT PRIOR | ACTIVE PROTEASOME INHIBITOR | IN-VIVO CYTOTOXICITY | THALIDOMIDE PLUS DEXAMETHASONE | RANDOMIZED PHASE-III | INTERNATIONAL STAGING SYSTEM | CHRONIC LYMPHOCYTIC-LEUKEMIA | PHARMACOLOGY & PHARMACY | HIGH-DOSE MELPHALAN | STEM-CELL TRANSPLANTATION | UNDETERMINED SIGNIFICANCE MGUS | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - chemistry | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Proteasome Inhibitors - chemistry | Multiple Myeloma - immunology | Multiple Myeloma - drug therapy | Antibodies, Monoclonal, Humanized - administration & dosage | Multiple Myeloma - enzymology | Precision Medicine | Antibodies, Monoclonal, Humanized - adverse effects | Immunologic Factors - chemistry | Antibodies, Monoclonal, Humanized - therapeutic use | Proteasome Inhibitors - administration & dosage | Immunologic Factors - administration & dosage | Treatment Outcome | Clinical Trials as Topic | Drug Discovery | Proteasome Inhibitors - adverse effects | Proteasome Inhibitors - therapeutic use | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Immunologic Factors - adverse effects | Antibodies, Monoclonal, Humanized - chemistry | Immunologic Factors - therapeutic use
Journal Article